Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295

NCT03737123 is registered in ClinicalTrials.gov with Nabil Adra as lead sponsor.

NCT NCT03737123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03737123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: HCRN GU17-295
Lead sponsor
Nabil Adra
Phase
Phase 2
Overall status
Terminated
Start date
December 19, 2018
Completion date
May 18, 2022
Enrollment
6 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma